MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing 10.08.2026, 07:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
MindMaze Therapeutics Holding 0,258 EUR ±0,00 % L&S Exchange

MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous
MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing

10-Aug-2026 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing

Geneva, Switzerland — August 10, 2026 — MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today provided updates on two previously announced initiatives supporting its strategic priorities in neurology: the completion of its organizational simplification initiative, and the implementation of its CHF 8.0 million strategic equity financing with Neuro.io Group SA (Neuro.io). Together, these initiatives further support the execution of the Company's U.S. commercial priorities and the advancement of its neurotherapeutics platform.

Completion of Organizational Simplification
The Company has completed its organizational simplification initiative through a series of transactions, including the disposal of substantially all remaining non-neurology legacy operations acquired through its business combination with Relief Therapeutics. The transactions included a combination of upfront cash consideration and potential future contingent consideration, with the primary objective of simplifying the Company's operations, reducing its cost base and focusing its operations on its core neurology business.

Update on Neuro.io Equity Financing
Separately, the Company provided an update on its CHF 8.0 million strategic equity financing with Neuro.io. The Company has completed the initial tranche of the financing and received gross cash proceeds of CHF 4.0 million. In connection with the first tranche, 4,970,000 treasury shares were transferred to Neuro.io, and newly issued CHF 2,850,900 mandatory convertible loan notes were converted into 12,395,217 ordinary shares in accordance with the terms of the financing.

The parties have agreed to revise the funding schedule for the second CHF 4.0 million tranche. Under the revised schedule, the second tranche is expected to be funded in two installments during September and November 2026. The definitive financing agreement remains in effect, and the economic terms of the remaining investment remain unchanged.

While the parties continue to work toward completion of the remaining investment, there can be no assurance as to its timing or completion. Alongside the Neuro.io financing, the Company is actively pursuing additional financing to support its liquidity and will provide further updates as material developments occur.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The Company’s FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


Additional features:


File: Ad hoc release_MindMaze_Corporate and Financing Update

End of Inside Information
Language: English
Company: MindMaze Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
Fax: +41 22 545 11 17
E-mail: ir@mindmazetherapeutics.com
Internet: www.mindmazetherapeutics.com
ISIN: CH1251125998
Listed: SIX Swiss Exchange
EQS News ID: 2379618

 
End of Announcement EQS News Service

2379618  10-Aug-2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Exklusiv für BörsenNEWS.de User

Sichern Sie sich bis zum 31.08.2026 ein Depot bei Smartbroker+ und erhalten Sie einen Anteil Ihrer Lieblingsaktie im Wert von 50 Euro.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer